Skip to content
TriangleGet started
← Back to this collection

PUBLICATIONS · 32511983

Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2020 Jul
First author
Salles G

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jul;21(7):870-872. doi: 10.1016/S1470-2045(20)30275-8.
    note
    Source null
    related pmid
    32511984
    relationship
    Comment in

Authors and identifiers

  1. name
    Salles G
    type
    Author
  2. name
    Duell J
    type
    Author
  3. name
    González Barca E
    type
    Author
  4. name
    Tournilhac O
    type
    Author
  5. name
    Jurczak W
    type
    Author
  6. name
    Liberati AM
    type
    Author
  7. name
    Nagy Z
    type
    Author
  8. name
    Obr A
    type
    Author
  9. name
    Gaidano G
    type
    Author
  10. name
    André M
    type
    Author
  11. name
    Kalakonda N
    type
    Author
  12. name
    Dreyling M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Salles G
    type
    Author
  2. name
    Duell J
    type
    Author
  3. name
    González Barca E
    type
    Author
  4. name
    Tournilhac O
    type
    Author
  5. name
    Jurczak W
    type
    Author
  6. name
    Liberati AM
    type
    Author
  7. name
    Nagy Z
    type
    Author
  8. name
    Obr A
    type
    Author
  9. name
    Gaidano G
    type
    Author
  10. name
    André M
    type
    Author
  11. name
    Kalakonda N
    type
    Author
  12. name
    Dreyling M
    type
    Author
bibliography ids
  1. nci-bib-50d0d1d76f3a848328bab591
book metadata
content sha256
8dc7e03b71102bede74be10c7529b7a15287e91e3d37220978366bd9f1231294
document type
citation
dois
  1. 10.1016/S1470-2045(20)30225-4
electronic publication date
display
2020 Jun 5
precision
day
year
2020
evidence scope
bibliographic_metadata_only
id
pubmed:32511983
immutable id
pubmed:32511983@8dc7e03b71102bede74be10c7529b7a15287e91e3d37220978366bd9f1231294
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
7
name
The Lancet. Oncology
nlm unique id
100957246
pages
978-988
volume
21
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2020 Jul;21(7):870-872. doi: 10.1016/S1470-2045(20)30275-8.
    note
    Source null
    related pmid
    32511984
    relationship
    Comment in
outcomes validated
false
pmid
32511983
provenance
batch id
40d9eae1f1d369f13109
provider
NCBI PubMed ESummary
record sha256
b17b14abfa6ab64e92c7fec7b5dfab2ad3f74ccf79122a74b34bd93d9debe1b3
response sha256
03fa1567b6babd78281d8ec4529596b9d4953c2c4ac23257dca371d609645ba9
retrieved at
2026-09-09T23:47:52.637547+00:00
publication date
display
2020 Jul
precision
month
year
2020
publication types
  1. Clinical Trial, Phase II
  2. Journal Article
  3. Multicenter Study
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/32511983/
title
Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study.

Preserved source evidence · Independent clinical review pending · Not medical advice